Ligand Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Ligand Pharmaceuticals's earnings have been declining at an average annual rate of -64.6%, while the Pharmaceuticals industry saw earnings declining at 2.2% annually. Revenues have been declining at an average rate of 0% per year. Ligand Pharmaceuticals's return on equity is 11.9%, and it has net margins of 81.4%.

Key information

-64.6%

Earnings growth rate

-60.3%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	-0.005%
Return on equity	11.9%
Net Margin	81.4%
Last Earnings Update	31 Mar 2024

Recent past performance updates

Recent updates

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Mar 17

Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year

Dec 31

Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Dec 03

Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?

Oct 11

Revenue & Expenses Breakdown
Beta

How Ligand Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:LGND Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 24	118	96	53	-1
31 Dec 23	131	54	53	0
30 Sep 23	154	21	68	0
30 Jun 23	180	41	68	0
31 Mar 23	204	51	69	0
31 Dec 22	196	-5	70	0
30 Sep 22	183	23	46	0
30 Jun 22	188	27	44	0
31 Mar 22	223	45	46	0
31 Dec 21	242	76	47	0
30 Sep 21	275	68	49	0
30 Jun 21	252	48	51	0
31 Mar 21	208	39	47	0
31 Dec 20	164	7	39	0
30 Sep 20	143	-16	45	0
30 Jun 20	126	-25	39	0
31 Mar 20	110	-61	40	0
31 Dec 19	120	629	42	0
30 Sep 19	153	594	43	0
30 Jun 19	174	677	43	0
31 Mar 19	239	764	41	0
31 Dec 18	251	143	38	0
30 Sep 18	242	179	34	0
30 Jun 18	230	120	32	0
31 Mar 18	168	53	29	0
31 Dec 17	141	13	29	0
30 Sep 17	129	16	28	0
30 Jun 17	117	9	27	0
31 Mar 17	109	-3	28	0
31 Dec 16	109	-2	28	0
30 Sep 16	92	7	27	0
30 Jun 16	88	205	25	0
31 Mar 16	87	235	25	0
31 Dec 15	72	230	25	0
30 Sep 15	74	231	24	0
30 Jun 15	71	33	25	0
31 Mar 15	63	11	23	0
31 Dec 14	65	12	23	0
30 Sep 14	56	7	21	0
30 Jun 14	54	8	19	0
31 Mar 14	53	10	19	0
31 Dec 13	49	9	18	0
30 Sep 13	48	10	18	0
30 Jun 13	41	7	17	0

Quality Earnings: LGND has a large one-off gain of $118.8M impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: LGND's current net profit margins (81.4%) are higher than last year (25.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: LGND's earnings have declined by 64.6% per year over the past 5 years.

Accelerating Growth: LGND's earnings growth over the past year (87.7%) exceeds its 5-year average (-64.6% per year).

Earnings vs Industry: LGND earnings growth over the past year (87.7%) exceeded the Pharmaceuticals industry 3.7%.

Ligand Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Key information

Recent past performance updates

First quarter 2024 earnings released: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ligand Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 08, 2023

Recent updates

First quarter 2024 earnings released: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 14, 2024

Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024

Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

CEO & Director exercised options to buy US$1.2m worth of stock.

Chief Financial Officer notifies of intention to sell stock

Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Announces Management Appointments

Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024

U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 28%, revenue upgraded

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ligand Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

CEO & Director recently bought US$238k worth of stock

Ligand Pharmaceuticals Incorporated Appoints Martine Zimmermann to its Board of Directors

Ligand Pharmaceuticals Incorporated Reaffirms Revenue Guidance for 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) announces an Equity Buyback for $50 million worth of its shares.

Ligand's Collaborator Merck Announces V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Ligand Pharmaceuticals Incorporated to Report Q2, 2023 Results on Aug 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a stalking horse asset purchase agreement to acquire Substantially All of the Assets of Novan, Inc. for $15 million.

Consensus EPS estimates increase by 73%

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Independent Chairman recently sold US$343k worth of stock

Independent Chairman notifies of intention to sell stock

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

Ligand Pharmaceuticals Incorporated Raises Earnings Guidance for 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 41%

Full year 2022 earnings released: US$0.31 loss per share (vs US$3.44 profit in FY 2021)

Ligand Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 22, 2023

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Executive Director notifies of intention to sell stock

Executive Director exercised options to buy US$998k worth of stock.

Ligand Pharmaceuticals Incorporated Announces CEO Changes

Price target decreased to US$111

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%

Insufficient new directors

Chief Financial Officer recently sold US$128k worth of stock

Price target decreased to US$131

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Year 2022

Insufficient new directors

Ligand Pharmaceuticals Incorporated Appoints Octavio (Tavo) Espinoza as Chief Financial Officer

Ligand Pharmaceuticals Incorporated to Report Q3, 2022 Results on Nov 07, 2022

Price target decreased to US$149

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

CEO & Executive Director notifies of intention to sell stock

CEO & Executive Director recently sold US$180k worth of stock

Consensus estimates of losses per share improve by 14%

Consensus revenue estimates increase by 11%

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Full Year 2022

Ligand Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 08, 2022

Ligand Pharmaceuticals Incorporated Appoints Jason Haas to its Board of Directors

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Investor sentiment improved over the past week

Consensus forecasts updated

Revenue & Expenses Breakdown
Beta